iwCLL 2019 | MRD determinations in venetoclax treatment of CLL

Nicolas Martinez-Calle

Nicolas Martinez-Calle, MD, Nottingham University Hospitals NHS Trust, Nottingham, UK, discusses minimal residual disease (MRD) determinations in venetoclax treatment of heavily pre-treated chronic lymphocytic leukemia (CLL) patients. This interview took place at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK.

Share this video